

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/02688

Title: Diagnostics and Therapeutics for Diseases Associated with Growth Hormone Secretagogue Receptor (GHS)

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
Susan M. Pellegrino  
Reg. No.: 48,972  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-6450  
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No.	Art Unit	Filing Date	App. No. Le A 35 943
INFORMATION DISCLOSURE CITATION		Applicant(s) Stefan GOLZ, et al.			

## U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION YES NO
	F1	0 1 9 2 2 9 2	06/12/01	WO			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Bednarek, M. A., et al., "Structure-Function Studies on the New Growth Hormone-Releasing Peptide, Ghrelin: Minimal Sequence of Ghrelin Necessary for Activation of Growth Hormone Secretagogue Receptor 1a", J. Med. Chem., 43(23): 4370-4376 (October 2000)
R2	Bodart, V., et al., "Identification and Characterization of a New Growth Hormone-Releasing Peptide in the Heart", Circulation Research, 85(9): 796-802 (October 1999)
R3	Katugampola, S. D., et al., "[ <sup>125</sup> I-His <sup>9</sup> ]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis", British Journal of Pharmacology, 134(1): 143-149 (September 2001)
R4	Nagaya, N., et al., "Hemodynamic and hormonal effects of human ghrelin in healthy volunteers", Am. J. Physiol. Regulatory Integrative Comp. Physiol., 280(5): R1483-R1487 (May 2001)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 2 2 2004